PRME

Prime Medicine, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03

Figures on this page computed 2026-11-08 12:48 UTC

Last close

4.97USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-03

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself
-4342.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
-3607.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.10 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.17x

1.59x

1.76x

n/a

0.72x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales2.17x
Its own average over 6 years, 2.1M.
Profit1.59x
Its own average over 7 years, -126.9M.
Free cash flow1.76x
Its own average over 7 years, -95.0M.
Debtn/a
Its own average over 1 year, 28.7M.
Price0.72x
Its own average over 5 years, 7. Market data, 2026-11-04

Sales is furthest from its own average, at 2.17 times.

Sales is 2.17 times its own 6-year average; Profit is 1.59 times its own 7-year average; Free cash flow is 1.76 times its own 7-year average; Price is 0.72 times its own 5-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales against its own 6-year average2.17
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
The filing itself
Profit against its own 7-year average1.59
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
The filing itself
Free cash flow against its own 7-year average1.76
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
The filing itself
Debt against its own 1-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-013569
Reported in
USD
The filing itself
Price against its own 5-year average0.72Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD